Article Text

Download PDFPDF
Response to: ‘Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria’ by Cavagna et al
  1. James B Lilleker1,2,
  2. Jiri Vencovsky3,
  3. Guochun Wang4,
  4. Lucy R Wedderburn5,
  5. Louise P Diederichsen6,
  6. Jens Schmidt7,
  7. Paula Jordan8,
  8. Olivier Benveniste9,
  9. Maria Giovanna Danieli10,
  10. Katalin Dankó11,
  11. Nguyen Thi Phuong Thuy12,
  12. Monica Vázquez-Del Mercado13,
  13. Helena Andersson14,
  14. Boel De Paepe15,
  15. Jan L De Bleecker15,
  16. Britta Maurer16,
  17. Liza J McCann17,
  18. Nicolo Pipitone18,
  19. Neil McHugh19,20,
  20. Zoe Betteridge19,20,
  21. Paul New21,
  22. Robert G Cooper21,22,
  23. William E Ollier22,
  24. Janine A Lamb22,
  25. Niels Steen Krogh23,
  26. Ingrid E Lundberg24,
  27. Hector Chinoy25,26
  28. On behalf of all EuroMyositis contributors
  1. 1 Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester, UK
  2. 2 Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust, Stott Lane, UK
  3. 3 Institute of Rheumatology, Prague, Czech Republic
  4. 4 Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China
  5. 5 University College London GOS Institute of Child Health and NIHR GOSH Biomedical Research Centre, Great Ormond Street Hospital for Children NHS Trust, London, UK
  6. 6 Department of Rheumatology, Odense University Hospital, Odense, Denmark
  7. 7 Department of Neurology, University Medical Center Göttingen, Göttingen, Germany
  8. 8 Myositis UK, Southampton, UK
  9. 9 Département de Médecine Interne et Immunologie Clinique, Hôpital Pitié-Salpêtrière, AP-HP, UPMC, Paris, France
  10. 10 Dipartimento di Scienze Cliniche e Molecolari, Clinica Medica, Università Politecnica delle Marche and Ospedali Riuniti, Ancona, Italy
  11. 11 Division of Immunology, University of Debrecen, Debrecen, Hungary
  12. 12 Department of Rheumatology, Bach Mai Hospital, Hanoi Medical University, Hanoi, Vietnam
  13. 13 División de Medicina Interna, Servicio de Reumatología, PNPC 004086, CONACyT, Hospital Civil Dr Juan I Menchaca, Guadalajara, Jalisco, Salvador Quevedo y Zubieta S/N, Guadalajara, Mexico
  14. 14 Department of Rheumatology, Oslo University Hospital, Oslo, Norway
  15. 15 Department of Neurology, Ghent University Hospital, Ghent, Belgium
  16. 16 Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
  17. 17 Department of Rheumatology, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
  18. 18 Department of Rheumatology, Arcispedale S Maria Nuova-IRCCS of Reggio Emilia, Reggio Emilia, Italy
  19. 19 Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath, Bath, UK
  20. 20 Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
  21. 21 MRC-ARUK Institute for Ageing and Chronic Disease, University of Liverpool, Liverpool, UK
  22. 22 Division of Population Health, Health Services Research and Primary Care, Faculty of Biology, Medicine and Health, School of Health Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK
  23. 23 ZiteLab ApS, Frederiksberg, Denmark
  24. 24 Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
  25. 25 Rheumatology Department, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK
  26. 26 The National Institute for Health Research Manchester Musculoskeletal Biomedical Research Unit, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK
  1. Correspondence to Dr Hector Chinoy, Centre for Musculoskeletal Research, The University of Manchester, Manchester M13 9PT, UK; hector.chinoy{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Cavagna et al 1 for their thoughtful analysis relating to our recent publication.2 Several important points are raised, many of which we also referred to. It is of great interest and reassurance that the demographics and clinical features of antisynthetase syndrome (ASS) are broadly similar between the AENEAS (American and European NEtwork of Anti-Synthetase syndrome) and EuroMyositis cohorts. Clearly the frequency of interstitial lung disease and arthritis differs due to the sources of case ascertainment. This highlights …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles